Astrid Scalori Selected Research

Astrid Scalori Research Topics

5	Ulcerative Colitis 10/2022 - 10/2015
3	Crohn Disease (Crohn's Disease) 10/2022 - 10/2015
3	Chronic Hepatitis C 05/2016 - 02/2015
2	Hemorrhage 01/2022 - 01/2022
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2022 - 10/2015
2	Necrosis 01/2022 - 01/2022
2	Liver Diseases (Liver Disease) 10/2015 - 07/2009
2	Focal Nodular Hyperplasia 09/2002 - 02/2002
1	Appendicitis 01/2022
1	Disease Progression 01/2019
1	Drug-Related Side Effects and Adverse Reactions 01/2019
1	Idiopathic Pulmonary Fibrosis 01/2019
1	Exanthema (Rash) 01/2019
1	Fibrosis (Cirrhosis) 05/2016
1	Infections 01/2016
1	Sclerosing Cholangitis 10/2015
1	Inflammation (Inflammations) 10/2015
1	Colitis 10/2015
1	Glycogen Storage Disease Type I 05/2012
1	Liver Cell Adenoma (Hepatocellular Adenoma) 05/2012

4	etrolizumabIBA 10/2022 - 01/2022
2	Ribavirin (Virazole)FDA LinkGeneric 01/2016 - 02/2015
2	Hormones (Hormone)IBA 09/2002 - 02/2002
1	Tumor Necrosis Factor InhibitorsIBA 01/2022
1	Adalimumab (Humira)FDA Link 01/2022
1	pirfenidoneIBA 01/2019
1	Antiviral Agents (Antivirals)IBA 05/2016
1	danoprevirIBA 05/2016
1	Ritonavir (Norvir)FDA Link 05/2016
1	Protease Inhibitors (Protease Inhibitor)IBA 01/2016
1	peginterferon alfa-2a (Pegasys)FDA Link 01/2016
1	telaprevirIBA 01/2016
1	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 01/2016
1	2'- fluoro- 2'- methyl- 3',5'- diisobutyryldeoxycytidineIBA 01/2016
1	RNA (Ribonucleic Acid)IBA 01/2016
1	azidoiodophenethylamidosuccinylcymarin (AISC)IBA 10/2015
1	Leukocyte L1 Antigen Complex (Calgranulin)IBA 10/2015
1	Capsules (Microcapsules)IBA 10/2015
1	Glucose-6-PhosphateIBA 05/2012
1	GlycogenIBA 05/2012
1	Toll-Like Receptors (Toll-Like Receptor)IBA 07/2009
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2009
1	InterleukinsIBA 07/2009
1	Oral ContraceptivesIBA 02/2002

2	Therapeutics 01/2022 - 01/2022
1	Remission Induction 01/2022